Trial Profile
An Open-Label Study to Evaluate the Effect of a Single Dose of Briakinumab on the Pharmacokinetics of Single Doses of Caffeine, Tolbutamide, Omeprazole, Metoprolol, and Midazolam in Subjects With Moderate to Severe Psoriasis.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Briakinumab (Primary) ; Caffeine; Metoprolol; Midazolam; Omeprazole; Tolbutamide
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Abbott Laboratories
- 10 Aug 2011 Planned end date changed from 1 Mar 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
- 10 Aug 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 10 Aug 2011 Actual initiation date (Apr 2011) added as reported by ClinicalTrials.gov.